AVE-9488

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H14FNO
Molecular Weight	255.2869
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC1=CC=C(C=C1)C(=O)NC2CC3=CC=CC=C3C2

InChI

InChIKey=BOFMSBVSYVESTM-UHFFFAOYSA-N

InChI=1S/C16H14FNO/c17-14-7-5-11(6-8-14)16(19)18-15-9-12-3-1-2-4-13(12)10-15/h1-8,15H,9-10H2,(H,18,19)

HIDE SMILES / InChI

Molecular Formula	C16H14FNO
Molecular Weight	255.2869
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:29:08 GMT 2023` Edited by `admin` on `Sat Dec 16 11:29:08 GMT 2023`
Record UNII	9U46KWJ9UF
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AVE-9488

Common Name

English

4-FLUORO-N-(INDAN-2-YL)BENZAMIDE

Systematic Name

English

AVE 9488

Code

English

N-(2,3-DIHYDRO-1H-INDEN-2-YL)-4-FLUOROBENZAMIDE

Systematic Name

English

4-FLUORO-N-INDAN-2-YL-BENZAMIDE

Systematic Name

English

BENZAMIDE, N-(2,3-DIHYDRO-1H-INDEN-2-YL)-4-FLUORO-

Systematic Name

English

Code System Code Type Description

CAS

291756-32-6

Created by admin on Sat Dec 16 11:29:08 GMT 2023 , Edited by admin on Sat Dec 16 11:29:08 GMT 2023

PRIMARY

FDA UNII

9U46KWJ9UF

Created by admin on Sat Dec 16 11:29:08 GMT 2023 , Edited by admin on Sat Dec 16 11:29:08 GMT 2023

PRIMARY

PUBCHEM

10131276

Created by admin on Sat Dec 16 11:29:08 GMT 2023 , Edited by admin on Sat Dec 16 11:29:08 GMT 2023

PRIMARY

SMS_ID

300000042398

Created by admin on Sat Dec 16 11:29:08 GMT 2023 , Edited by admin on Sat Dec 16 11:29:08 GMT 2023

PRIMARY

Related Record Type Details


					9U46KWJ9UF

AVE-9488

ACTIVE MOIETY

Comments:

We investigated whether the impaired neovascularization capacity of ICMP patient-derived progenitor cells can be restored by pretreatment with the novel endothelial NO synthase (eNOS) transcription enhancer AVE9488 (AVE). Ex vivo pretreatment of BMC from patients with ICMP with AVE significantly increased eNOS mRNA expression by 2.1-fold (P < 0.05) and eNOS activity as assessed by ESR by >3-fold (P < 0.05). The increased eNOS expression was associated with an enhanced migratory capacity in vitro (P < 0.01) and improved neovascularization capacity of the infused BMC in an ischemic hind limb model in vivo (P < 0.001).


					9U46KWJ9UF

AVE-9488

ACTIVE MOIETY

Comments:

We tested the effects of the eNOS enhancer AVE 9488 on cardiac ischemia/reperfusion injury in vivo in mice. After treatment with the eNOS enhancer AVE 9488 (30 mg/kg/day) or placebo for one week mice underwent 30 min of coronary artery ligation and 24 h of reperfusion in vivo. Ischemia-reperfusion damage was significantly reduced in mice treated with the eNOS enhancer when compared to placebo treated mice (infarct/area at risk 65.4 +/- 4.1 vs. 36.9 +/- 4.0%, placebo vs. eNOS enhancer, P = 0.0002).